References
- Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, Sanpaolo MG, . Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multi center case–control study. Blood 2003;102:996–9.
- Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H, Engels EA. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007;297:2010–7.
- Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology 2003;125:1723–32.
- Marignani M, Mangone M, Cox MC, Angeletti S, Veggia B, Ferrari A, . HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens. Dig Liver Dis 2011;43:139–42.
- Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, . Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol ;27:605–11.
- Marzano A, Angelucci E, Andreone P, . Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007;39:397–408.
- Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002;3:333–40.
- Ennishi D, Terui Y, Yokoyama M, . Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol 2008;83:59–62.
- Hsieh CY, Huang HH, Lin CY, . Rituximab-induced hepatitis C virus reactivation after spontaneous remission in diffuse large B-cell lymphoma. J Clin Oncol 2008;26: 2584–6.
- Tsutsumi Y, Ichiki K, Shiratori S, . Changes in hepatitis C virus antibody titer and viral RNA load in non-Hodgkin's lymphoma patients after rituximab chemotherapy. Int J Lab Hematol 2009;31:468–70.
- Besson C, Canioni D, Lepage E, . Characteristic and outcome of diffuse large B-cell lymphoma in hepatitis C-positive patients in LNH 93 and LNH 98 Groupe d’Etude des Lymphomes de l’Adulte programs. J Clin Oncol 2006;6: 953–60.
- National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Available at: http://ctep.cancer.gov/protocolDevelopment/electronicapplications/docs/ctcaev3.pdf (accessed).
- Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, . Hepatic toxicity and prognosis in HCV-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010; .
- Visco C, Arcaini L, Brusamulino E, . Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol 2006;17:1434–40.
- Arcaini L, Merli M, Passamonti F, . Impact of treatment-related liver toxicity on the outcome of HCV-positive non Hodgkin's lymphomas. Am J Hematol 2010;85:46–50.
- Musto P, Dell’Olio M, La Sata A, . Diffuse B-large cell lymphomas (DBLCL) with hepatitis C virus (HCV) infection: clinical outcome and preliminary results of a pilot study combining R-CHOP with antiviral therapy. Blood 2005; 106:2447.